Development of OXY111A, a novel hypoxiamodifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial.

Saved in:

Bibliographic Details
Title:	Development of OXY111A, a novel hypoxiamodifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial.
Authors:	Limani, Perparim^1,2, Linecker, Michael^1,2, Kron, Philipp^1,2, Samaras, Panagiotis^1,3, Pestalozzi, Bernhard^1,3, Stupp, Roger^1,3, Jetter, Alexander⁴, Dutkowski, Philipp^1,2, Müllhaupt, Beat⁵, Schlegel, Andrea^1,2, Nicolau, Claude⁶, Lehn, Jean-Marie⁷, Petrowsky, Henrik^1,2, Humar, Bostjan^1,2, Graf, Rolf^1,2, Clavien, Pierre-Alain^1,2 clavien@access.uzh.ch
Source:	BMC Cancer. 10/19/2016, Vol. 16, p1-6. 6p. 2 Diagrams, 1 Chart.
Database:	Academic Search Ultimate

Description
ISSN:	14712407
DOI:	10.1186/s12885-016-2855-3